Interstitial Cystitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | UCB Pharma, Lipella Pharma, Allergan, PureTech Health, Imbrium Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Interstitial Cystitis pipeline constitutes 8+ key companies continuously working towards developing 10+ Interstitial Cystitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Interstitial Cystitis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Cystitis Market.

The Interstitial Cystitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Interstitial Cystitis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Interstitial Cystitis treatment therapies with a considerable amount of success over the years.

*
Interstitial Cystitis companies working in the treatment market are UCB Pharma, Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others, are developing therapies for the Interstitial Cystitis treatment

*
Emerging Interstitial Cystitis therapies in the different phases of clinical trials are- Certolizumab pegol, Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others are expected to have a significant impact on the Interstitial Cystitis market in the coming years.

*
In March 2025, Imbrium Therapeutics, a subsidiary of Purdue Pharma, announced the completion of the final patient visit in its Phase 1b clinical trial (NCT06285214) assessing the investigational oral therapy sunobinop (V117957) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).

*
In March 2025, Hyloris reported a favorable interim review for its ALENURA clinical trial, with the Independent Data Monitoring Committee (IDMC) recommending the study's continuation. Patient enrollment is anticipated to conclude by the end of 2025. ALENURA is being developed as a potential first-line therapy for interstitial cystitis.

*
In April 2024, Glycologix, Inc. ("Glycologix"), a clinical-stage biopharma company specializing in biopolymer therapies for soft tissue protection and repair, announced that results from its multi-center Phase 1b trial of GLX-100 in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) will be presented at the 2025 American Urological Association (AUA) Annual Meeting.

*
In June 2023, Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialized biopharmaceutical firm dedicated to meeting unmet medical requirements by reimagining existing medications, announced the enrollment of the first participant in a Phase 2 trial for AlenuraTM. This trial involves four arms and compares the product candidate to its individual components, heparin and lidocaine, as well as a placebo. AlenuraTM is an innovative bladder instillation product in its clinical stage, integrating lidocaine, a well-known anesthetic, in a novel alkalinized formulation with heparin, a glycoso-amino-glycan (GAG), found in bladder mucous membranes. AlenuraTM shows promise as a potential primary pharmaceutical treatment for acute pain among patients diagnosed with interstitial cystitis/bladder pain syndrome.

Interstitial Cystitis Overview

Interstitial Cystitis, also known as Bladder Pain Syndrome (BPS), is a chronic condition characterized by inflammation and irritation of the tissues lining the wall of the bladder. It is a type of painful bladder syndrome that can lead to discomfort, pressure, and pain in the pelvic region. The exact cause of interstitial cystitis is not well understood, and it can be challenging to diagnose.

Get a Free Sample PDF Report to know more about Interstitial Cystitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/interstitial-cystitis-pipeline-insight [https://www.delveinsight.com/report-store/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Interstitial Cystitis Drugs Under Different Phases of Clinical Development Include:

*
Certolizumab pegol: UCB Pharma

*
Sunobinop: Imbrium Therapeutics

*
IMB 150: PureTech Health

*
SI-722: Seikagaku Corporation

*
IW-3300: Ironwood Pharmaceuticals, Inc.

*
Peppermint oil: Integrative Therapeutics, Inc.

*
Ferumoxytol: Lipella Pharmaceuticals, Inc.

*
BOTOX: Allergan

*
VNX001: Vaneltix Pharma, Inc./Prevail Infoworks, Inc

Interstitial Cystitis Route of Administration

Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Interstitial Cystitis Molecule Type

Interstitial Cystitis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Interstitial Cystitis Pipeline Therapeutics Assessment

*
Interstitial Cystitis Assessment by Product Type

*
Interstitial Cystitis By Stage and Product Type

*
Interstitial Cystitis Assessment by Route of Administration

*
Interstitial Cystitis By Stage and Route of Administration

*
Interstitial Cystitis Assessment by Molecule Type

*
Interstitial Cystitis by Stage and Molecule Type

DelveInsight's Interstitial Cystitis Report covers around 10+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Interstitial Cystitis product details are provided in the report. Download the Interstitial Cystitis pipeline report to learn more about the emerging Interstitial Cystitis therapies [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Interstitial Cystitis Therapeutics Market include:

Key companies developing therapies for Interstitial Cystitis are - Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Ironwood Pharmaceuticals, Inc., Vaneltix Pharma, Inc., Prevail Infoworks, Inc., and others.

Interstitial Cystitis Pipeline Analysis:

The Interstitial Cystitis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Cystitis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Cystitis Treatment.

*
Interstitial Cystitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Interstitial Cystitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Cystitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Interstitial Cystitis drugs and therapies [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Interstitial Cystitis Pipeline Market Drivers

*
Increase in prevalence of Interstitial Cystitis, increase in Research and Development are some of the important factors that are fueling the Interstitial Cystitis Market.

Interstitial Cystitis Pipeline Market Barriers

*
However, lack of approved drugs, lack of understanding about the cause of the disease and other factors are creating obstacles in the Interstitial Cystitis Market growth.

Scope of Interstitial Cystitis Pipeline Drug Insight

*
Coverage: Global

*
Key Interstitial Cystitis Companies: UCB Pharma, Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others

*
Key Interstitial Cystitis Therapies: Certolizumab pegol, Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others

*
Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies

*
Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers

Request for Sample PDF Report for Interstitial Cystitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Interstitial Cystitis Report Introduction

2. Interstitial Cystitis Executive Summary

3. Interstitial Cystitis Overview

4. Interstitial Cystitis- Analytical Perspective In-depth Commercial Assessment

5. Interstitial Cystitis Pipeline Therapeutics

6. Interstitial Cystitis Late Stage Products (Phase II/III)

7. Interstitial Cystitis Mid Stage Products (Phase II)

8. Interstitial Cystitis Early Stage Products (Phase I)

9. Interstitial Cystitis Preclinical Stage Products

10. Interstitial Cystitis Therapeutics Assessment

11. Interstitial Cystitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Interstitial Cystitis Key Companies

14. Interstitial Cystitis Key Products

15. Interstitial Cystitis Unmet Needs

16 . Interstitial Cystitis Market Drivers and Barriers

17. Interstitial Cystitis Future Perspectives and Conclusion

18. Interstitial Cystitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-cystitis-pipeline-2025-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-ucb-pharma-lipella-pharma-allergan-puretech-health-imbrium-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.